Results 41 to 50 of about 164,343 (265)

Triple-Negative Breast Cancer: Emerging Biomarkers for Early Diagnosis, Prognosis, and Treatment [PDF]

Middle East Journal of Cancer
Breast cancer (BC) is a heterogeneous disease characterized by significant global mortality and incidence rates. Annually, approximately 1 million cases of BC are diagnosed worldwide, with over 170,000 classified as triple-negative.
Zahra Roshanizadeh, Mohammad Reza Haghshenas, Abbas Ghaderi   +2 more
doaj   +1 more source

Current Issues and Clinical Evidence in Tumor-Infiltrating Lymphocytes in Breast Cancer [PDF]

Journal of Pathology and Translational Medicine, 2015
With the advance in personalized therapeutic strategies in patients with breast cancer, there is an increasing need for biomarker-guided therapy. Although the immunogenicity of breast cancer has not been strongly considered in research or practice, tumor-
Sung Gwe Ahn, Joon Jeong, SoonWon Hong, Woo Hee Jung   +3 more
doaj   +1 more source

Huaier-induced suppression of cancer-associated fibroblasts confers immunotherapeutic sensitivity in triple-negative breast cancer.

Phytomedicine
BACKGROUND Triple-negative breast cancer (TNBC) is the most intractable subgroup of breast neoplasms due to its aggressive nature. In recent years, immune checkpoint inhibitors (ICIs) have exhibited potential efficacy in TNBC treatment.
Chen Li, Xiaolong Wang, Luyao Xing, Tong Chen, Wenhao Li, Xin Li, Yifei Wang, Chao Yang, Qifeng Yang   +8 more
semanticscholar   +1 more source

An epithelial GPR35 isoform supports tumor‐associated transcriptional and metabolic phenotypes

FEBS Letters, EarlyView.
GPR35 generates two functionally distinct isoforms with previously unresolved roles. GPR35‐short mediates immune‐cell chemotaxis, while GPR35‐long is enriched in colorectal cancer epithelium, where it supports increased metabolism, proliferation, and tumor‐associated transcriptional programs.
Jørgen D. Rønneberg, Martine Hjeltnes, Josephine Krieger, Joshua E. Elias, Maria Stensland, Kristian Holm, Xiaojun Jiang, Chuki Khangsar, Tuula A. Nyman, Arthur Kaser, Johannes R. Hov, Tom H. Karlsen, Nicole C. Kaneider, Frode L. Jahnsen, Georg Schneditz   +14 more
wiley   +1 more source

Different activity and toxicity of immunotherapy in monozygotic twins diagnosed with early triple-negative breast cancer: a case report

Therapeutic Advances in Medical Oncology
Breast cancer (BC) is the most common malignancy among women. Among 5%–10% of diagnoses are correlated with hereditary cancer syndromes, while the remaining cases are sporadic and linked to multiple factors.
M. Perachino, L. Del Mastro, Giulia Buzzatti, Lucia Trevisan, M. Razeti, Andrea Bellodi, S. Spinaci, Davide Soldato, M. Lambertini, F. Poggio   +9 more
semanticscholar   +1 more source

Epigenetic reprogramming of lineage switching in cancer

FEBS Letters, EarlyView.
Cancer cells rarely commit to a single identity. Epigenetic mechanisms and tumor microenvironment cues push epithelial cells toward flexible, hybrid states that can shift into mesenchymal, neuroendocrine, or stem‐like fates, driving metastasis, drug resistance, and tumor heterogeneity. Targeting the epigenetic regulators behind these transitions, using
Ezgi Boyvatlı, Burcu Akman, Ezgi Bağırsakçı, Nese Atabey, Serap Erkek‐Ozhan   +4 more
wiley   +1 more source

CAR-T cell therapy in triple-negative breast cancer: Hunting the invisible devil

Frontiers in Immunology, 2022
Triple-negative breast cancer (TNBC) is known as the most intricate and hard-to-treat subtype of breast cancer. TNBC cells do not express the well-known estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 (HER2 ...
Fatemeh Nasiri, Fatemeh Nasiri, Mehrasa Kazemi, Seyed Mohamad Javad Mirarefin, Maral Mahboubi Kancha, Milad Ahmadi Najafabadi, Faeze Salem, Setareh Dashti Shokoohi, Sahar Evazi Bakhshi, Pouya Safarzadeh Kozani, Pooria Safarzadeh Kozani   +10 more
doaj   +1 more source

Rare case of myelodysplastic syndrome with excess blasts 2 developing after adjuvant chemoradiotherapy for triple-negative breast cancer in a patient with Bloom syndrome

Strahlentherapie und Onkologie (Print)
Bloom syndrome (BS) is a rare autosomal recessive disorder caused by a loss-of-function mutation in the BLM gene encoding an RecQ helicase involved in DNA repair and maintenance of chromosomal stability.
Ali Fuat Gürbüz, M. Eryılmaz, O. Yıldız, Fahriye Kılınç, Murat Araz, M. Artaç   +5 more
semanticscholar   +1 more source

Keratin 19 as a prognostic marker and contributing factor of metastasis and chemoresistance in high‐grade serous ovarian cancer

Molecular Oncology, EarlyView.
Keratin 19 (KRT19) is overexpressed in high‐grade serous ovarian cancer with high levels of Kallikrein‐related peptidases (KLK) 4–7 and is associated with poor survival. In vivo analyses demonstrate that elevated KRT19 increases peritoneal tumour burden.
Sophia Bielesch, Isabel Vogel, Sina Nokodian, Johanna Moeller, Antonia Blechschmidt, Vicky Hecht, Vanessa Kuentzel, Katharina Thiedig, Melissa Schwab, Oliver Schilling, Holger Bronger, Marion Kiechle, Viktor Magdolen, Tobias Dreyer   +13 more
wiley   +1 more source

Assessment of the Relationship of Treated Basal-Type Breast Cancer with Recurrence, Metastasis, and Chemotherapy Regimen at A Tertiary Hospital Over Five Years

Novelty in Biomedicine
Background: Some studies suggest that basal-type breast cancer is a subtype of triple-negative breast cancer, and some others mention that it is a unique type of breast cancer.
Mehran Sharifi Esfahani, Samaneh Ahmadi, Mahtab Taatii Moghadam   +2 more
doaj   +1 more source